MedTrace Logo

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

NCT04197934 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-03-30

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous system metastases). WSD0922-FU is a targeted treatment which blocks the EGFR protein - a strategy that has led to a lot of benefit in patients with many different cancers. WSD0922-FU may also be able to get into cancers in the brain and spinal cord and help patients with brain and spinal cord cancers.

Funding Source - FDA OOPD

Conditions

  • Anaplastic Astrocytoma, IDH-Wildtype
  • Glioblastoma, IDH-Wildtype
  • Metastatic Lung Non-Small Cell Carcinoma
  • Metastatic Malignant Neoplasm in the Central Nervous System
  • Stage IV Lung Cancer AJCC v8

Interventions

PROCEDURE

Biospecimen Collection - blood samples

Undergo collection of blood samples

PROCEDURE

Biospecimen Collection - CSF samples

Undergo collection of CSF samples

PROCEDURE

Computed Tomography

Undergo CT

DRUG

EGFR/EGFRvIII Inhibitor WSD0922-FU

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgical resection

Sponsors & Collaborators

Principal Investigators

  • Sani H. Kizilbash, M.D., M.P.H. · Mayo Clinic in Rochester

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-20
Primary Completion
2022-10-30
Completion
2031-02-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04197934 on ClinicalTrials.gov